1 MilnerR. Growth hormone 1985.BrMedJ 1985;291:15934. 2 Ross M. Production of medically important polypeptides using recombinant DNA technology. In: Gueriguian JL, ed. Insulins, growth hormone, and recmbinan DNA technology. New York: Raven Press, 1981:33-48. 3 Rosenfeld R, Hintz R, Johanson A, Genentech CoUlaborative Group. Prospective, randomized trial of methionyl growth hormone and/or oxandrolone in Turner syndrome. Pediaar Res 1985;19:620. 4 Frazer T, Gavin J, Doughaday W, Hillman R, Weldon V. Growth hormone-dependent growth failure.I Pediatr 1982;101:12-5. 5 Van Vliet G, Styne D, Kaplan S, Grumbach M. Growth hormone treatment for-short stature. NEnglJ7Med 1983;309:1016-22. 6 Grunt J, Howard C, Doughaday W. Comparison of growth and somatomedin C responses foHowing growth hormone treatment in children with small-for-date short stature, significant idiopathic short stature and hypopituitarism. Acta Endoamol (Copeh) 1984;106:168-74. 7 Gertner J, Genel M, Gianfredi S, etal. Prospectiveclinical trialofhumangrowth hormonein short children without growth hormone deficiency.J7Pediar 1984;104:172-6. 8 Marshall W. The relationship of variations in children's growth rates to seasonal climatic variations. AnnHu Biol 1975;2:243-50. 9 Barratt T, Broyer M, Chantler C, et al. Assessment of growth. AmJ7 Kidney Dis 1986;7:340-6. 10 Preece M. Experience of treatment with pituitary-derived hGH with special reference to immunological aspects. In: Milner RDG, Flodh H, eds. Imnnooiical aspects ofhson growth hormone. Oxford: Medical Education Services, 1986:9-16. 11 Preece M. Creutzfeldt-Jacob disease: implications for growth hormone deficient children. NewopadhlApplNewobo (in press).